Quick Answer
BioNexus Gene Lab Corp reported Total Revenue of $9.51 million for the year ending 2024.
- BioNexus Gene Lab Corp showed a decrease of -2.7% in Total Revenue from 2023 to 2024.
- This data is from BioNexus Gene Lab Corp's annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2018 to 2024 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $111.3 thousand | Q3 2018: $91.6 thousand | Q1 2019: $28.1 thousand | Q2 2019: $21.6 thousand | Q3 2019: $24.2 thousand | Q1 2020: $3.07 million | Q2 2020: $1.10 million | Q3 2020: $3.09 million | Q1 2021: $3.45 million | Q2 2021: $3.09 million | Q3 2021: $3.58 million | Q1 2022: $3.03 million | Q2 2022: $2.49 million | Q3 2022: $2.58 million | Q1 2023: $2.38 million | Q2 2023: $2.57 million | Q3 2023: $2.55 million | Q1 2024: $2.38 million | Q2 2024: $1.97 million | Q3 2024: $2.63 million | Q1 2025: $2.14 million | Q2 2025: $2.26 million | Q3 2025: $2.54 million.
- Over the full 7 years of available data (2018 to 2024), BioNexus Gene Lab Corp's Total Revenue has grown by 4,379.2%.
- Historical annual values: Fiscal year 2024: $9.51 million | Fiscal year 2023: $9.77 million | Fiscal year 2022: $10.93 million | Fiscal year 2021: $13.36 million | Fiscal year 2020: $11.39 million | Fiscal year 2019: $127.0 thousand | Fiscal year 2018: $212.3 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: